Review

Systemic sclerosis-associated interstitial lung disease - proposed recommendations for future randomized clinical trials.

D. Khanna, K.K. Brown, P.J. Clements, R. Elashoff, D.E. Furst, J. Goldin, J.R. Seibold, R.M. Silver, D.P. Tashkin, A.U. Wells

CER3839
2010 Vol.28, N°2 ,Suppl.58
PI 0055, PF 0062
Review

Free to view
(click on article PDF icon to read the article)

PMID: 20576216 [PubMed]

Received: 10/05/2010
Accepted : 11/05/2010
In Press: 24/06/2010
Published: 24/06/2010

Abstract

Pulmonary disease is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Recent well-designed trials in SSc-associated interstitial lung disease (SSc-ILD) have provided important insights regarding outcome measures and trial design. Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review.